Current perspectives on the optimal management of infantile hemangioma

Abstract

Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy for a traditionally surgical disease. This review provides readers with an overview of IH, treatment modalities, and addresses specific considerations in IH disease management.

Keywords:

• infantile hemangioma
• medical treatment indications
• propranolol
• complications of infantile hemangioma

Acknowledgments

All patients gave consent for their images to be published in this review article; guardian consent was obtained for patients under the age of 18 years.

Disclosure

The authors report no conflicts of interest in this work.